Showing 2731-2740 of 5771 results for "".
- Topcon Healthcare Acquires Intelligent Retinal Imaging Systemshttps://modernod.com/news/topcon-healthcare-acquires-intelligent-retinal-imaging-systems-to-enhance-connected-care-across-primary-and-eye-care/2482909/Topcon Healthcare announced the acquisition of Intelligent Retinal Imaging Systems (IRIS), a US-based provider of cloud-based retinal screening technology. FInancial terms of the deal were not disclosed. IRIS bri
- Boehringer Ingelheim and Re-Vana Therapeutics Collaborate to Develop Long-Acting Ophthalmic Therapieshttps://modernod.com/news/boehringer-ingelheim-and-re-vana-therapeutics-announce-collaboration-to-develop-long-acting-ophthalmic-therapies/2482905/Boehringer Ingelheim and Re-Vana Therapeutics announced a strategic collaboration and license agreement designed to accelerate the development of first-in-class extended-release therapies for vision-threatening eye diseases.
- Alcon Showcases Surgical Efficiency of Unity VCS Innovations at ASRS 2025https://modernod.com/news/alcon-showcases-surgical-efficiency-of-unity-vcs-innovations-at-asrs-2025/2482903/Alcon will showcase its latest clinical data and innovations at the 2025 American Society of Retina Specialists (ASRS) annual meeting, July 31 to August 2, in Long Beach, California. Attendees can explore Alcon’s latest surgical advancements through scientific presentations and hands-on dem
- Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindnesshttps://modernod.com/news/opus-genetics-and-the-global-rdh12-alliance-partner-to-advance-rdh12-gene-therapy-for-inherited-childhood-blindness/2482902/Opus Genetics announced a partnership with the Global RDH12 Alliance to advance Opus’ gene therapy program for patients with vision loss due to retinol dehydrogenase 12 (RDH12) gene mutations. The Alliance serves as a collaborative platform uniting advocacy groups dedicated to RDH
- The Vision Council Releases Updated Version of Data Communication Standardhttps://modernod.com/news/the-vision-council-releases-updated-version-of-data-communication-standard/2482899/The Vision Council announced the official release and approval of Version 3.14 of its Data Communication Standard in an effort to advance the efficiency, accuracy, and interoperability of optical manufacturing systems.
- Topcon Partners with OKKO Health to Advance Home-Based Vision Monitoring and Patient Engagementhttps://modernod.com/news/topcon-partners-with-okko-health-to-advance-home-based-vision-monitoring-and-patient-engagement/2482894/Topcon Healthcare announced an investment in OKKO Health, a UK-based provider of vision testing software. While financial terms of the deal were not disclosed, the investment positions Topcon as the lead in OKKO Health’s seed funding round.
- Viatris Fails Phase 3 Study of MR-139 for Blepharitishttps://modernod.com/news/viatris-fails-phase-3-study-of-mr-139-for-blepharitis/2482893/Viatris announced that its phase 3 study evaluating the efficacy and safety of pimecrolimus 0.3% (MR-139) for blepharitis did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing. The MR-139 3001 phase 3 trial cons
- Altris AI Launches Altris Sync App Allowing AI to Directly Sync to OCT Deviceshttps://modernod.com/news/altris-ai-launches-altris-sync-app-allowing-ai-to-directly-sync-to-oct-devices-ai-now-connects-to-oct-devices-from-8-manufacturers-and-enables-analysis-of-historical-data/2482891/Altris AI announces the release of 'Altris Sync,' a secure application that syncs AI directly to OCT devices from 8 OCT manufacturers. The introduction of Altris Sync for automated upload of OCT files is desinged to remove the need for manual operations and bring AI de
- Harrow Enters into Commercialization Agreement with Samsung Bioepis for Biosimilars Portfolio in the UShttps://modernod.com/news/harrow-enters-into-commercialization-agreement-with-samsung-bioepis-for-ophthalmology-biosimilars-portfolio-in-the-us/2482890/Harrow announced that it has entered into a definitive agreement with Samsung Bioepis to secure the exclusive US commercial rights to the ophthalmology biosimilar portfolio of Samsung Bioepis, which includes Byooviz (ranibizumab-nuna), an FDA-ap
- Stuart Therapeutics Publishes New Study Demonstrating Potential of Collagen Mimetic Peptides in Treating Ophthalmic Diseasehttps://modernod.com/news/stuart-therapeutics-publishes-new-study-demonstrating-potential-of-collagen-mimetic-peptides-in-treating-ophthalmic-disease/2482887/Stuart Therapeutics announced the publication of a preclinical study in Pharmaceuticals highlighting the potential of collagen mimetic peptides (CMPs) in restor